- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
This study is testing new combinations of medicines for advanced stomach or gastroesophageal junction cancer. It's looking at how safe they are and how well they help control the cancer, especially in people with a specific marker called DKK1-high.
For: Gastric cancer · Gastric Adenocarcinoma · GastroEsophageal CancerGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study looks at a new drug, DKN-01, combined with standard treatments for advanced bowel cancer. It compares this new combination to the standard treatments alone, to see if it helps people live longer without their cancer growing.
For: Colorectal CancerGermany